FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (COVID-19), in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo
(Reuters) – The European health regulator said on Monday it had received an application from U.S. drugmaker Gilead Sciences Inc for approval of its antiviral drug, remdesivir, as a potential COVID-19 treatment in Europe.
“The assessment of the benefits and risks of remdesivir is being performed under a reduced timeline and an opinion could be issued within weeks,” the European Medicines Agency said in its statement. (bit.ly/2Yg8siD)
Reporting by Pushkala Aripaka in Bengaluru; Editing by Ramakrishnan M.